Jacobio Pharmaceuticals Group Co
Jacobio Pharmaceuticals Group Co., a leading biopharmaceutical company, is headquartered in Shanghai, China, with significant operations across Asia and beyond. Founded in 2016, Jacobio has rapidly established itself in the oncology sector, focusing on innovative drug discovery and development. The company is renowned for its unique approach to targeted therapies, particularly in the development of small molecule drugs that address unmet medical needs in cancer treatment. Jacobio's core products include advanced therapeutics that leverage cutting-edge technology to enhance efficacy and reduce side effects. With a strong market position, Jacobio has achieved notable milestones, including successful clinical trials and strategic partnerships that bolster its research capabilities. As a key player in the biopharmaceutical industry, Jacobio Pharmaceuticals continues to drive advancements in cancer care, positioning itself as a pioneer in the field.
DitchCarbon Score
How does Jacobio Pharmaceuticals Group Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jacobio Pharmaceuticals Group Co's score of 24 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Jacobio Pharmaceuticals Group Co's reported carbon emissions
In 2023, Jacobio Pharmaceuticals Group Co reported total carbon emissions of approximately 2.7 million tonnes CO2e, comprising about 153,390 tonnes CO2e from Scope 1 emissions and around 2.55 million tonnes CO2e from Scope 2 emissions. This represents a slight increase from 2022, where total emissions were about 2.56 million tonnes CO2e, with Scope 1 emissions at approximately 148,170 tonnes CO2e and Scope 2 emissions at about 2.41 million tonnes CO2e. In 2021, the company recorded total emissions of about 2.49 million tonnes CO2e, with Scope 1 emissions at approximately 58,370 tonnes CO2e and Scope 2 emissions at around 2.43 million tonnes CO2e. Despite these figures, Jacobio Pharmaceuticals has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company operates within an industry context that increasingly prioritises sustainability and carbon footprint reduction, yet it currently lacks formal commitments to align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 58,370 | 000,000 | 000,000 |
| Scope 2 | 2,431,850 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jacobio Pharmaceuticals Group Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
